C
Charles D. Blanke
Researcher at University of British Columbia
Publications - 106
Citations - 17049
Charles D. Blanke is an academic researcher from University of British Columbia. The author has contributed to research in topics: Imatinib mesylate & Medicine. The author has an hindex of 33, co-authored 87 publications receiving 16100 citations. Previous affiliations of Charles D. Blanke include University of Michigan & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).
Robert P. Whitehead,Cathryn Rankin,Paulo M. Hoff,Philip J. Gold,Kevin G. Billingsley,Robert Chapman,Lucas Wong,John H. Ward,James L. Abbruzzese,Charles D. Blanke +9 more
TL;DR: Romidepsin at this dose and schedule is ineffective in the treatment of patients with metastatic colorectal cancer after prior chemotherapy and future trials might evaluate combinations of romidepsIn with chemotherapeutic or other agents.
Book ChapterDOI
Gastrointestinal Stromal Tumors
TL;DR: Treatment of advanced GIST patients with STI571, a novel selective tyrosine kinase inhibitor, results in remission rates that approach 60% and overall tumor control rates of 85%, and can serve as a paradigm for designing molecularly targeted therapies for other malignancies.
Journal ArticleDOI
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.
Petri Bono,Andreas Krause,Margaret von Mehren,Michael Heinrich,Charles D. Blanke,Sasa Dimitrijevic,George D. Demetri,Heikki Joensuu +7 more
TL;DR: A high serum SCF/KIT ratio may increase SCF-induced cell signaling with prolonged imatinib treatment, at the time when imatinIB treatment is withdrawn, and in patients whose GIST has wild-type receptors.
Journal ArticleDOI
Protocol for the examination of specimens from patients with gastrointestinal stromal tumor.
Brian P. Rubin,Charles D. Blanke,George D. Demetri,Ronald P. DeMatteo,Christopher D.M. Fletcher,John R. Goldblum,Jerzy Lasota,Alexander J. Lazar,Robert G. Maki,Markku Miettinen,Amy Noffsinger,Mary Kay Washington,Thomas Krausz +12 more
TL;DR: It becomes even more important for pathologists to familiarize themselves with these protocols and cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of these documents.
Journal Article
End points in advanced colon cancer clinical trials : A review and proposal. Commentary
Carmen J. Allegra,Charles D. Blanke,Marc Buyse,Richard M. Goldberg,Axel Grothey,Neal J. Meropol,Leonard B. Saltz,Alan P. Venook,Greg Yothers,Daniel J. Sargent +9 more
TL;DR: In this investigation, bevacizumab did not seem to improve the PFS of oxaliplatin-based regimens to the extent expected based on prior trials.